OncoTargets and Therapy

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advances in Cancer Immunotherapy: Harnessing the Immune System for Cancer Treatment" in OncoTargets and Therapy.

In the last decade, harnessing the immune system with immune checkpoint blockades has achieved remarkable results in solid tumors of different histotypes, enabling durable responses and long-term survival. Despite these unprecedented results, primary or acquired resistance can limit its efficacy; thus, a deeper understanding of the underlying mechanisms of resistance is crucial for the identification of novel therapeutic strategies in several clinical settings (e.g. adjuvant, neo-adjuvant setting, rare tumors, etc.). Immunotherapy research needs to answer some key questions, from mechanistic exploration of lack of response, to biomarker identification, to the development of novel immunotherapeutic modalities and their clinical application. 

We are seeking original research and review article submissions on cancer immunotherapy, including but not limited to the following subtopics:

• Immune-checkpoint blockade for cancer treatment: from biology to clinical results

• Therapeutic Combinations of Immune-Modulating Antibodies

• Immunotherapy of brain metastases and brain primary tumors

• Cancer immunotherapy in ocular melanoma

• Immunotherapy in rare tumors

• Immunotherapy in adjuvant and neoadjuvant setting

• Mechanisms of immune escape and potential strategies to overcame resistance

• Epigenetic immune remodeling to improve efficacy of cancer immunotherapy

• Harnessing T cell metabolism to improve anti-tumor response

• Microbiome and immune-checkpoint blockade therapy

• Beyond immune-checkpoint(s): new targets for cancer immunotherapy

• Imaging challenges of immunotherapy

• Biomarkers of response and toxicity of immunotherapy

• Radiomics and deep learning approach in cancer immunotherapy

The deadline for submissions is 1 August 2025. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code JALHG for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

Guest advisor

Anna Maria Di Giacomo, University Hospital of Siena

Anna Maria Di Giacomo is an Associate Professor of Oncology at the University of Siena, Chair of the Early Phase Clinical Trial Center and Associate Director for the Center for Immuno-Oncology, Department of Oncology at the University Hospital of Siena. She is a member of the Associazione Italiana di Oncologia Medica (AIOM), the Italian Network for Tumour Biotherapy (NIBIT) Foundation, The Italian Melanoma Intergroup (IMI) and ESMO (European Society of Clinical Oncology). She is also a member of the Board of Director of NIBIT Foundation, of IMI and of Federation of Italian Cooperative Oncology Groups (FICOG). She is a member of Steering Committee of ESMO Immuno-oncology. 

Prof. Di Giacomo is currently Principal Investigator and Co-Investigator for more than 150 clinical trials in solid malignancies, investigating bio-chemotherapy, immunotherapeutic agents and molecularly targeted agents. Her clinical and translational research interests include: the immunological and clinical activity of immunotherapeutic agents including the new generation of targeted immunotherapy in the treatment of skin, brain and other solid tumours; epigenetics and epigenetic-immuno-sequencing strategies to improve efficacy of cancer immunotherapy; and identification of biomarkers of efficacy of cancer immunotherapy.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Radiation Therapies for Cancer" in OncoTargets and Therapy.

Radiation therapy remains a cornerstone in the treatment of various cancers. With continuous advancements in technology and a deeper understanding of cancer biology, radiation therapies are becoming more precise and effective. This Article Collection seeks to explore these advancements, including novel radiation techniques, toxicity management, and integration of radiation therapies with other treatment modalities.

We invite papers on topics including but not limited to:

• Innovative radiation techniques, including proton therapy, carbon ion therapy, and stereotactic body radiotherapy (SBRT).
• Technological innovations in radiation oncology, including the development and implementation of technologies such as artificial intelligence, machine learning, and image-guided radiation therapy (IGRT) in clinical practice.
• Radiation therapy and immunotherapy combinations.
• Personalized radiation therapy
• Radiation-induced toxicity management

The deadline for submissions is 1 December 2025. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code MMCTR for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection